Kerry FisherKerry is dedicated to exploring how best to deliver therapeutic viruses, genes and proteins into the tumour microenvironment. As well as bridging the gap between our commercial and scientific strategies, he holds a lectureship with the University of Oxford. Previously with PsiOxus, Kerry has over 25 years’ experience in translating oncolytic viruses from new product innovation all the way through early clinical trials to commercial development. During his career, Kerry has filed more than a dozen patent applications and has authored over sixty peer-reviewed publications. Kerry has a PhD in Therapeutic Gene Delivery from the University of Birmingham.